Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Buy
66
PODD Quote, Financials, Valuation and Earnings
Last price:
$259.84
Seasonality move
:
8.27%
Day range:
$258.75 - $262.84
52-week range:
$160.19 - $289.46
Dividend yield:
0%
P/E ratio:
45.03x
P/S ratio:
9.30x
P/B ratio:
15.11x
Volume:
465.4K
Avg. volume:
798K
1-year change:
58.8%
Market cap:
$18.3B
Revenue:
$2.1B
EPS (TTM):
$5.79
Analysts' Opinion
-
Consensus RatingInsulet has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $312.27, Insulet has an estimated upside of 19.78% from its current price of $260.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $234.00 representing 100% downside risk from its current price of $260.71.
Fair Value
-
According to the consensus of 18 analysts, Insulet has 19.78% upside to fair value with a price target of $312.27 per share.
PODD vs. S&P 500
-
Over the past 5 trading days, Insulet has overperformed the S&P 500 by 1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Insulet does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Insulet has grown year-over-year revenues for 37 quarters straight. In the most recent quarter Insulet reported revenues of $597.5M.
Earnings Growth
-
Insulet earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Insulet reported earnings per share of $1.39.
Enterprise value:
18.7B
EV / Invested capital:
--
Price / LTM sales:
9.30x
EV / EBIT:
54.67x
EV / Revenue:
9.05x
PEG ratio (5yr expected):
0.46x
EV / Free cash flow:
63.27x
Price / Operating cash flow:
65.02x
Enterprise value / EBITDA:
44.25x
Gross Profit (TTM):
$1.4B
Return On Assets:
14.72%
Net Income Margin (TTM):
20.19%
Return On Equity:
43.11%
Return On Invested Capital:
17.64%
Operating Margin:
18.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.3B | $1.7B | $2.1B | $509.8M | $597.5M | |
| Gross Profit | $805.6M | $1.2B | $1.4B | $361.2M | $430.9M | |
| Operating Income | $37.6M | $220M | $308.9M | $106.4M | $109.3M | |
| EBITDA | $106.9M | $323.6M | $423.7M | $133.3M | $141.5M | |
| Diluted EPS | $0.06 | $2.91 | $5.79 | $1.44 | $1.39 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1.3B | $1.3B | $1.6B | $1.9B | |
| Total Assets | $1.9B | $2B | $2.3B | $2.6B | $3.1B | |
| Current Liabilities | $207.8M | $228.8M | $364.7M | $451.2M | $528.4M | |
| Total Liabilities | $1.3B | $1.5B | $1.8B | $1.9B | $1.9B | |
| Total Equity | $603.6M | $556.3M | $476.4M | $732.7M | $1.2B | |
| Total Debt | $1.1B | $1.3B | $1.4B | $1.4B | $1.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $119M | $145.7M | $430.3M | $45.2M | $147.7M | |
| Cash From Investing | -$191.1M | -$119.4M | -$146.2M | -$31.6M | -$68M | |
| Cash From Financing | -$40.3M | -$13.6M | -$28.1M | $2.2M | -$20.9M | |
| Free Cash Flow | -$38.3M | $36.5M | $296.3M | $13.6M | $91.7M | |
PODD
Sector
Market Cap
$18.3B
$35M
Price % of 52-Week High
90.07%
44.47%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
58.81%
-38.53%
Beta (5-Year)
1.300
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$250.39
200-day SMA
Buy
Level
$243.63
Bollinger Bands (100)
Sell
Level
255.78 - 277.56
Chaikin Money Flow
Buy
Level
103.3M
20-day SMA
Buy
Level
$254.39
Relative Strength Index (RSI14)
Buy
Level
53.06
ADX Line
Buy
Level
16.81
Williams %R
Sell
Level
-16.8289
50-day SMA
Sell
Level
$262.77
MACD (12, 26)
Sell
Level
-2.97
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
124.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.4462)
Sell
CA Score
(Annual)
Level (-0.3568)
Buy
Beneish M-Score
(Annual)
Level (-2.3643)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-0.7395)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Stock Forecast FAQ
In the current month, PODD has received 14 Buy ratings 4 Hold ratings, and 0 Sell ratings. The PODD average analyst price target in the past 3 months is $312.27.
-
Where Will Insulet Stock Be In 1 Year?
According to analysts, the consensus estimate is that Insulet share price will rise to $312.27 per share over the next 12 months.
-
What Do Analysts Say About Insulet?
Analysts are divided on their view about Insulet share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Insulet is a Sell and believe this share price will drop from its current level to $234.00.
-
What Is Insulet's Price Target?
The price target for Insulet over the next 1-year time period is forecast to be $312.27 according to 18 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is PODD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Insulet is a Buy. 14 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PODD?
You can purchase shares of Insulet via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Insulet shares.
-
What Is The Insulet Share Price Today?
Insulet was last trading at $259.84 per share. This represents the most recent stock quote for Insulet. Yesterday, Insulet closed at $260.71 per share.
-
How To Buy Insulet Stock Online?
In order to purchase Insulet stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 28
Saia [SAIA] is down 2.41% over the past day.
Sell
48
APPF alert for Apr 28
AppFolio [APPF] is up 1.49% over the past day.
Sell
15
KNSL alert for Apr 28
Kinsale Capital Group [KNSL] is up 2.2% over the past day.
